Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
ActiveOps 89.5p £63.9m (AOM.L)
A provider of Management Process Automation (MPA) software for running hybrid and global back-office operations, announces the appointment to the Board of Emma Salthouse as Chief Financial Officer, with effect from 1 December 2023. Ken Smith, current Chief Financial Officer, has decided to step down from his position on the Board on that date, remaining with the Company on a part-time basis for a number of months to oversee an orderly transition of responsibilities. Emma is a CIMA qualified, experienced finance professional and was previously the Head of Finance at ActiveOps for c.five years, before joining Forensic Access Limited, a provider of forensic science expertise, as Group CFO.
Celadon Pharmaceuticals 147.5p £77.9m (CEL.L)
A UK-based pharmaceutical company focused on the development, production and sale of cannabis-based medicines, announces that it has entered into a new contract for the commercial sale of its cannabis product with a second UK pharmaceutical company customer that the Company anticipates could generate up to £1.2m in revenue. The Company anticipates that the first shipment will be made in Q4 2023 and the contract will run over a three year term, with both parties retaining the option to extend for a further two years subject to mutual agreement. Under the terms of that contract, the company will supply a minimum of £3m worth of product over the next three years.
Evgen Pharma 2.35p £6.5m (EVG.L)
A clinical stage drug development company developing sulforaphane-based medicines, announces that Non-Executive Chair, Barry Clare, will be retiring as Chairman of the Board and a director of the Company at the next board meeting on 21 September 2023. The role of Chair will be passed to Dr Susan Foden, currently Senior Non-executive Director, on an interim basis. The Company also announces the appointment of Toni Hänninen as interim Chief Financial Officer following Richard Moulson's retirement in July. Toni was previously CFO at Faron Pharmaceuticals Ltd, and holds over 20 years of experience in business development and senior finance roles.
Gamma Communications £10.84 £1051.2m (GAMA.L)
A provider of Unified Communications as a Service (UCaaS) into the UK and European business markets, announces its unaudited results for the six months ended 30 June 2023. Revenue and gross profit grew by 9% to £256.2m and £131.2m respectively (H1 2022: £234.7m and £120.4m), with gross margin being maintained and adjusted EBITDA growing by 9% to £56.5m (H1 2022: £51.9m). Profit before tax increased 13% to £43.5m (H1 2022: £38.4m) and the Company holds cash and cash equivalents less borrowings of £121.7m (H1 2022: £72.6m), an increase of 68%. Post period in August 2023, the Company acquired Satisnet Limited, a UK-based cyber security company and expects to be immediately earnings enhancing. The Company expect continued growth in EBITDA and adjusted EPS and expect to be in the top half range of market expectations.
GRC International Group 6.5p £7.0m (GRC.L)
An integrated cyber security and privacy solutions business, announces its audited year end results for 12 months to 31 March 2023 (FY23). Revenue up 6% to £14.7m (FY22: £13.9m), gross margin of 61% (FY22: 59%) - continued improvement reflects operational gearing from subscription services and internal efficiencies from automation projects. Adjusted EBITDA decreased by 70% to 0.3m (FY22: £1.0m) and loss before tax increased by 60% to £1.6m (FY22: 1.0m) and cash balance of £0.1m with borrowings of £1.3m. The Company increased the value of SaaS subscriptions customers - at period end we had over 3,000 SaaS customers with an average value of £1.2k, a 5% year-on-year increase. Trading remains in line with expectations for FY24.
Johnson Service Group 130.7p £551.5m (JSG.L)
A UK textile services provider announces its interim results for the six months ended 30 June 2023. Total revenue increased by 22.0% to £215.0m (June 2022: £176.2m), as a result adjusted EBITDA of £57.7m (June 2022: 42.8m) an increase of c.35% and operating profit increased by 140% to £16.1m (June 2022: £6.7m). The Company holds free cash flow of £17.9m and has total net debt of £40.5m, largely attributed to the share buyback initially completed with £19.7m deployed since 1 January 2023. The Company has also invested £12.9m across the estate and committed to a new site in the South-East to further improve operational efficiencies, increase capacity and support innovation. Full year outturn expected to be slightly ahead of current market expectations.
Michelmersh Brick Holdings 88.5p £83.3m (MBH.L)
The brick manufacturer and brick-fabricator, reports its half year results for the six months ended 30 June 2023. Revenue increased 23.5% to £42.0m (HY22: £34.0m), as a result operating profit of £6.1m, up 7.0% (HY22: £5.7m ) and profit before tax of £6.1m was up 8.9% (HY22: £5.6m). Adjusted EBITDA of £8.7m (HY22: £8.1m ) is ahead by 7.4% against 2022 and profit before tax of £6.1m (HY22: £5.6m) up 8.9%. The Company held net cash of £11.8m and undrawn £20m borrowing facility. The Company launched “SustainableBrick.com”, a new website that highlights the benefits of clay brick to our broad customer base and the Board is confident to meet full year expectations.
SkinBioTherapeutics 22.3p £38.5m (SBTX.L)
The life science business focused on skin health, has announced that it has chosen the probiotic blends it will use for the comparative studies for its consumer study in acne. The two separate blends will be tested side-by-side in a consumer volunteer study to determine which has better efficacy. The Company is aiming to target the inflammatory pathways that are associated with irritable skin conditions like acne. An independent third-party will conduct the study and run two separate cohorts in parallel to compare the efficacy, this is provided by Dutch food supplement provider; Winclove Probiotics BV. The study is expected to commence in Q4 2023 and be complete by year end with results issued thereafter.
Tissue Regenix Group 53.8p £37.9m (TRX.L)
The regenerative medical devices company, reports its unaudited interim results for the six months ended 30 June 2023 (H1 2023). Group revenues increased by 19% to USD14.1m (H1 2022: USD11.8m), gross profit for the period increased to 49% (H1 2022: 46%) and adjusted EBITDA profit* of USD0.4m against an adjusted EBITDA loss of USD0.5m in H1 2022. Cash position at 30 June 2023 of USD4.1m (30 June 2022: USD6.2m) and is sufficient to support current business growth plan. The Company completed an addition of a UK distributor for OrthoPure XT and distribution agreements for China and Australia. The Group continue to build on momentum and expect growth in 2023 to be above market expectations.
XLMedia 12p £31.2m (XLM.L)
The digital media company that manages a portfolio of premium brands with an emphasis on sports and gaming in regulated markets, announces that it has signed an exclusive three-year partnership with Atlanta Journal-Constitution, LLC (AJC). AJC reaches over 9.2 million unique digital users per month and the partnership with AJC represents another win for XLMedia's Media Partnership Business, expanding the Group's established footprint in Georgia and the Southern states of the US. This agreement will enable AJC to capture new revenue streams whilst providing their readership with new content offerings. The partnership also allows XLMedia to reach AJC's national readership in currently legal live sports betting markets.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
